Corestemchemon Completes Application for Manufacturing Site Change Approval for 'Neuronata-Alzu'…'Full-Scale Sales Expected'
Predicted impact: Medium
Manufacturing site change filing for Neuronata-Alzu; sales hopes, revenue base small at about ₩18B
Corestemchemon코아스템켐온
166480 · KOSDAQ · ₩166480 · 코아스템켐온
₩1,636▼ ₩24 (1.45%)End-of-day · Oct 30, 2026 · End-of-day prices.
Price · 1Y +4.34%
- Market cap
- ₩86B
- Enterprise value
- ₩119B
- P/E
- —
- P/B
- 1.9×
- Dividend yield
- 0.0%
- ROE
- −62.6%
- Net margin
- −152.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−73.2% from the high
₩1,014Today: ₩1,605 – ₩1,682₩6,100
Returns
- 1W−3.2%
- 1M−26.0%
- 3M−9.6%
- 6M−50.7%
- YTD−11.5%
- 1Y+4.3%
- Volume today
- 56,061
- 0.4× the 20-day average
- Traded today
- ₩91M
- Listed shares
- 52,870,376
- EPS (12 months)
- −₩526
- Earnings yield −32.1%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: One headline reports a regulatory step and expected sales growth. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-25% over the last month; the price is below its 20-day average.
- News impactSome3 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Corestemchemon stock overview
Corestemchemon (코아스템켐온, KRX: 166480) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops, manufactures and sells stem cell therapies for rare and intractable diseases, and its approved cell therapy Neuronata-R (for ALS/Lou Gehrig's disease) was first launched in 2015. Its shares closed at ₩1,636 on Oct 30, 2026, down 1.45% on the day, giving it a market value of ₩86B.
Key facts
- Market cap
- ₩86B
- Sector
- Biotech & Pharma
- Latest price change
- −1.45%
- As of
- Oct 30, 2026
- Main business
- The company develops, manufactures and sells stem cell therapies for rare and intractable diseases, and its approved cell therapy Neuronata-R (for ALS/Lou Gehrig's disease) was first launched in 2015.
Quick answers about Corestemchemon
- What does Corestemchemon do?
- The company develops, manufactures and sells stem cell therapies for rare and intractable diseases, and its approved cell therapy Neuronata-R (for ALS/Lou Gehrig's disease) was first launched in 2015. Following its 2022 merger with Chemon, it also runs a preclinical contract research organization (CRO) business that provides non-clinical safety and efficacy testing services for drug developers, which is its main source of revenue. The company's operations are based in South Korea, with production facilities in Yongin and Osong.
- What is the market cap of Corestemchemon?
- The market capitalisation of Corestemchemon was ₩86B at the close on Oct 30, 2026.
- Who are the largest shareholders of Corestemchemon?
- According to the latest official filings, the largest reported holders are Kim Gyeong-suk (10.89%, as of Sep 3, 2026); Yang Gil-an (2.27%, as of Dec 24, 2025); Lee Tae-yong (1.29%, as of Dec 24, 2025).
- When is the next earnings report from Corestemchemon?
- Korean companies rarely announce results dates in advance. Based on when Corestemchemon filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Corestemchemon?
- Yes. The National Pension Service held 0.02% of Corestemchemon shares as of Dec 31, 2024.
Company profile
The company develops, manufactures and sells stem cell therapies for rare and intractable diseases, and its approved cell therapy Neuronata-R (for ALS/Lou Gehrig's disease) was first launched in 2015. Following its 2022 merger with Chemon, it also runs a preclinical contract research organization (CRO) business that provides non-clinical safety and efficacy testing services for drug developers, which is its main source of revenue. The company's operations are based in South Korea, with production facilities in Yongin and Osong.
Written by AI from the company's latest annual report.
- Korean name
- 코아스템켐온
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 양길안
- Founded
- Dec 2003
- Listed
- Jun 2015
- Listed shares
- 52,870,376
- Fiscal year ends
- Month 12
- Website
- www.corestemchemon.com
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent news
Corestem ChemOn's 'Neuronata-R' clarifies follow-up clinical direction with FDA…Phase 3b pursued
Predicted impact: Low
FDA trial direction was already covered in recent news; no new financial impact.
Corestemchemon in FDA talks on Neuronata-R trial; two-track approach for US entry becomes visible
Predicted impact: Medium
FDA trial discussions for Neuronata-R are early-stage, but matter for a small biotech with little revenue.
Recent filings
See all- Exercise of Exchange Rights (2nd, 3rd, and 4th Series)Sep 4, 2026
- Insider shareholding reportSep 3, 2026
- 5%+ holding reportSep 3, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJul 8, 2026
Titles in Korean until English translations are added.
Also known as: Corestemchemon / 코아스템켐온 / 166480 / KRX:166480
Source: KRX statistical information